A multicenter observational study on the efficacy and tolerability of Privigen® (intravenous immunoglobulin preparation) - Interim analysis with focus on immune thrombocytopenia (ITP)

被引：0
|
作者：
Tschechne, B.
Otremba, B.
Lotichius, P. [1 ]
Pfruender, D. [1 ]
机构：
[1] CSL Behring, Hattersheim, Germany
来源：
ONKOLOGIE | 2011年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：170 / 171
页数：2
相关论文
共 46 条
  • [41] Retrospective, Observational, Multicenter Study Assessing the Thrombopoietin Receptor Agonist (TPO-RA) Romiplostim and Other Treatments for Patients with Newly Diagnosed or Persistent Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice in the United Kingdom (UK)
    McDonald, Vickie
    Bradbury, Charlotte
    Talks, Kate
    Lowe, Gillian
    Pavord, Sue
    Evans, Gillian
    Andiappan, Manoharan
    Sandschafer, Darcie
    Barbosa, Vitor Jose De Sousa
    Stephens, Lorraine
    Cooper, Nichola
    BLOOD, 2022, 140 : 2678 - 2680
  • [42] EFFICACY, SAFETY AND TOLERABILITY OF HUMAN IMMUNE GLOBULIN SUBCUTANEOUS, 20 % (IGSC 20 %): INTERIM ANALYSIS OF A PHASE 2/3 STUDY IN PATIENTS WITH PRIMARY IMMUNODEFICIENCIES (PID) IN NORTH AMERICA
    Suez, Daniel
    Melamed, Isaac
    Hussain, Iftikhar
    Stein, Mark
    Gupta, Sudhir
    Paris, Kenneth
    Fritsch, Sandor
    McCoy, Barbara
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2015, 35 (03) : 311 - 312
  • [43] Efficacy/Safety/Tolerability of Human Immune Globulin Subcutaneous, 20% (IGSC 20%): Interim Analysis of a Phase 2/3 Study in Patients with Primary Immunodeficiencies (PID) in North America
    Suez, D.
    Melamed, I.
    Hussain, I.
    Stein, M.
    Gupta, S.
    Paris, K.
    Engl, W.
    McCoy, B.
    Schiff, R. I.
    Yel, L.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S310 - S310
  • [44] Eltrombopag As Second Line Therapy in Adult Patients with Primary Immune Thrombocytopenia (ITP) in Attempt to Achieve Long-Term Remission. Preliminary Analysis of a Phase II, Multicenter, Prospective Study By Gimema Group (the ESTIT Study)
    Lucchini, Elisa
    Palandri, Francesca
    Volpetti, Stefano
    Vianelli, Nicola
    Auteri, Giuseppe
    Rossi, Elena
    Patriarca, Andrea
    Carli, Giuseppe
    Barcellini, Wilma
    Tosi, Patrizia
    Consoli, Ugo
    Valeri, Federica
    Santoro, Cristina
    Paoloni, Francesca
    Fazi, Paola
    Boggio, Elena
    Dianzani, Umberto
    Giardini, Ilaria
    Carpenedo, Monica
    Fanin, Renato
    Zaja, Francesco
    BLOOD, 2018, 132
  • [45] Safety and efficacy of the thrombopoietin receptor agonist Eltrombopag in patients with chronic Immune Thrombocytopenia (cITP) in routine healthcare - results of the 1st interim analysis of the non-interventional study RISA
    Meyer, O.
    Reiser, M.
    Doerfel, S.
    Schlag, R.
    Kaempfe, D.
    Welslau, M.
    Losem, C.
    Zahn, M. -O.
    von der Heyde, E.
    Ehrnsperger, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 195 - 196
  • [46] Multicenter observational study of the efficacy and safety of nivolumab (Nivo) as 2+line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim analysis
    Laktionov, K.
    Arzumanyan, A.
    Bolotina, L.
    Breder, V.
    Buevich, N.
    Danilova, A.
    Filippova, E.
    Kornietskaya, A.
    Kramchaninov, M.
    Kushniruk, E.
    Latipova, D.
    Moiseenko, F.
    Nikitina, T.
    Orlov, S.
    Orlova, R.
    Protsenko, S.
    Sarantseva, K.
    Stroyakovskiy, D.
    Ionova, T.
    ANNALS OF ONCOLOGY, 2017, 28
12345